国际肿瘤学杂志

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (7): 484-487.doi: 10.3760/cma.j.issn.1673422X.2014.07.002

• 综述 • 上一篇    下一篇

EML4ALK融合基因在肿瘤中的研究进展

郭易楠,岳文涛   

  1. 101149 首都医科大学附属北京胸科医院北京市结核病胸部肿瘤研究所细胞生物学实验室
  • 出版日期:2014-08-04 发布日期:2014-08-04
  • 通讯作者: 岳文涛，Email: yuewt2000@yahoo.com E-mail:yuewt2000@yahoo.com

EML4ALK fusion gene in tumor

 GUO  Yi-Nan, YUE  Wen-Tao   

  1. Department of Cellular & Molecular Biology，Tuberculosis and Thoracic Tumor Research Institute，Beijing Chest Hospital，Capital Medical University，Beijing 101149，China
  • Online:2014-08-04 Published:2014-08-04
  • Contact: YUE Wen-Tao E-mail:yuewt2000@yahoo.com

PDF

1401

摘要： 棘皮动物微管结合蛋白4(EML4)间变淋巴瘤激酶(ALK)融合基因作为近几年新发现的肿瘤相关基因，在多种肿瘤组织中表达。目前针对EML4ALK融合基因的研究仍以非小细胞肺癌为主，以该融合基因为治疗靶点的ALK抑制剂已经逐渐推向临床。EML4ALK融合基因与表皮生长因子受体（EGFR）Kras突变相关性的研究亦为肿瘤的靶向治疗提供了新思路。

关键词: 肿瘤, EML4ALK融合基因

Abstract: EML4ALK fusion gene is one of the novel targets in the therapy of lung cancer, which can be detected in several kinds of tumors. A specific ALK inhibitor has been shown to exert antitumor effects in nonsmall cell lung cancer with the EML4ALK fusion gene. Correlative study between EML4ALK gene fusion and EGFRKras mutations might cast new insight on the tumor target therapy.

Key words: Neoplasms, EML4ALK fusion gene